Press Releases (2005)

LPGA TOUR Pro Angela Jerman Teamed Up with Dermik Laboratories During Melanoma Month to Benefit The Women's Dermatologic Society, Help Educate Americans about Sun Exposure & Skin Health

BERWYN, PA — July 7, 2005 — Third year LPGA TOUR professional Angela Jerman teamed up with Dermik Laboratories during the month of May to remind consumers about the need for proper skin protection and forming good skin health habits. The American Academy of Dermatology (AAD) has designated May as Melanoma/Skin Cancer Detection and Prevention Month, with the first Monday in May designated as Melanoma Monday or "National Skin Self-Examination Day." Melanoma Monday kicks off the AAD program designed to raise awareness about skin health and encourage Americans to begin a life long habit of regular skin self-examinations. Dermik Laboratories will make a donation of $5,000 to The Women's Dermatologic Society (WDS) based on Angela's performance in LPGA Tour events during the month of May (a matching contribution of $5,000 will also be made to Jerman's charity of choice, the First Tee of Columbus, Georgia). The money donated by Dermik will be used to benefit WDS skin cancer screening and prevention initiatives as well as patient education.

"Our profession puts us at a higher risk of sun-related conditions due to sun exposure," said Angela Jerman, LPGA TOUR golf professional. "I am hoping we can raise awareness among the millions of American golf enthusiasts about the dangers of sun exposure and the steps they can take to minimize their risk. An additional goal of the program is to encourage the local community to be proactive about their skin health and go to see a dermatologist for a regular check-up."

During the month of May, Dermik Laboratories accumulated a donation to The Women's Dermatologic Society based on Angela's performance. Dermik pledged to donate $250 for every birdie, $500 for each eagle and $10,000 for every hole-in-one Angela made in competition during the month of May. Angela played in four events during May: the Michelob Ultra Open, the Chick-Fil-A Charity Championship, the Sybase Classic and the LPGA Corning Classic. Angela will also be working with the WDS at selected LPGA events in 2005 as their spokesperson for the "Play Safe in the Sun" campaign, a program designed to educate the golf community about skin cancer prevention and sun protection. This campaign is a part of the American Academy of Dermatology National Skin Cancer Volunteer Screening Initiative.

About Dermik Laboratories
Dermik Laboratories conducts the North American business of sanofi-aventis Dermatology, the global dermatology unit of sanofi-aventis. Dermik Laboratories has nearly 60 years of experience in the development, marketing and distribution of innovative prescription pharmaceutical products. Dermik has created a new division, Dermik Aesthetics, that will focus on marketing innovative, enduring, and reliable treatments to improve appearance and well-being. Dermik's mission is to foster healthy-looking skin and in turn, a healthy outlook for life.

About sanofi-aventis
The sanofi-aventis Group is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines. The sanofi-aventis Group conducts business in the U.S. through its subsidiaries Sanofi-Synthelabo Inc., Aventis Pharmaceuticals Inc. and Sanofi Pasteur Inc. The sanofi-aventis Group is listed in Paris (EURONEXT : SAN) and in New York (NYSE : SNY).

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. The statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expect", "anticipates", "believes", "intends", "estimates" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward looking information and statements. These risks and uncertainties include those discussed or identified in the public filing with the SEC and the AMF made by sanofi-aventis and Aventis, including those listed under "Forward-Looking Statements" and "Risk Factors" in the sanofi-aventis's annual report on Form 20-F for the year ending December 31, 2003 and those listed under "Cautionary Statement Regarding Forward-Looking Statements" and "Risk Factors" in Aventis's annual report on Form F-20 for the year ending December 31, 2003. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.